Faculty
-
August 30, 2016
Robert Klitzman on EpiPen's Price Hike
With EpiPen price-gouging in the news, Columbia's School of Professional Studies Bioethics Program Director, Dr. Robert Klitzman, has a new op-ed in CNN about the ethical questions raised by drug companies' overcharging patients. It's a tangled story of the principles of medicine, the profit priorities of private companies, and the taxpayers' money that creates these innovations.
Read the full article at CNN.
Faculty
From Silicon Valley Bank to Lehman Brothers, history shows that liquidity crises are often driven less by balance sheet metrics and more by confidence. In Columbia’s M.S. in Enterprise Risk Management program, students learn to assess both the quantitative and behavioral dimensions of liquidity risk.
Faculty
M.S. in Applied Analytics Professor Siddhartha Dalal traces his decades-long career in using AI to save lives.
Faculty
Accelerating electric vehicle adoption depends on advances in EV technology, public policies, and infrastructure investments.
All News
